Prosigna®/pam50 en la toma de decisiones clinicas en pacientes con cancer de mama

18 / 31

Prognostic value of PAM50 and risk of recurrence score in patients
with early stage breast cancer with long-term follow-up
Ohnstad et al. Breast Cancer Research (2017) 19:120
Observational Oslo1 study (1995–1998)